JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Overweight rating and announces Price Target of $28.
JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Overweight rating and announces Price Target of $28.